Stem cell banking and autologous biologics converge in an industry update that examines clinical, business and regulatory implications for practitioners and investors.
Key Takeaways
- Deal will combine autologous biologics including PRP, adipose-derived products and exosomes
- Forever Labs will provide stem cell collection, processing, and ISO-accredited cGMP storage
- Announcement cites recent Florida regulatory changes enabling expanded clinical and therapeutic pathways